Cross-Sector entity
Grail is most often covered alongside Bob Ragusa, which appears in 4 of these 7 stories. Across a 153-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 4. market-trends accounts for 2 of the 7 tracked stories, while 5 other categories carry the remainder.
7 verified stories tracked
Last mentioned: Jul 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Grail is most often covered alongside Bob Ragusa, which appears in 4 of these 7 stories. Across a 153-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 4. market-trends accounts for 2 of the 7 tracked stories, while 5 other categories carry the remainder. 0% of these stories carry negative sentiment. Grail appears in 7 tracked Cross-Sector stories published from February 20, 2026 through July 22, 2026. The tracked stories average 2.3 original sources each.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Grail. Shared-story counts are live from our verified record — not editorial picks.
Global Milestone Announcement
Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company.
FDA Breakthrough Device Designation
The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening.
ASCO Breakthrough 2026
Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore.
Market Outperformance
Grail shares end the week as a top performer in the healthcare sector, recouping major losses.
Volume Surge
Stock sees highest trading volume in six months as institutional buyers return.
TD Cowen Upgrade
TD Cowen upgrades Grail to 'Buy,' arguing the market overreacted to the leadership change.
Market Low
GRAL stock hits a 52-week low amid heavy selling pressure.
CEO Transition & Setback
CEO Bob Ragusa retires following reports of a clinical trial setback, causing a sharp drop in GRAL shares.
Leadership & Trial Volatility
CEO Bob Ragusa announces retirement; reports surface regarding a setback in the NHS-Galleri clinical trial.
Candel Public Offering
Candel Therapeutics prices $100M public offering at $5.45 per share.
Trial Data Release
Grail shares slide as NHS-Galleri trial misses primary endpoint for late-stage cancer reduction.
GDP Release
U.S. government scheduled to release Q4 GDP growth figures at 8:30 AM ET.
Grail Earnings
Grail reports Q4 and Full Year 2025 financial results, beating revenue and EPS estimates.
Gene Solutions' AI-powered multi-cancer liquid biopsy test, SPOT-MAS 10, gains FDA Breakthrough Device Designation after real-world data on 84,145 Asian individuals, signaling a new era for precision oncology emerging from Asia.
A massive real-world study and FDA Breakthrough Device Designation position SPOT-MAS 10 as a potential paradigm shift in multi-cancer screening across Asian healthcare systems, offering a non-invasive, population-validated tool to combat rising cancer burdens.
Source: thehindubusinessline.com · thehindu.com
After a volatile start to March marked by a CEO transition and clinical trial setbacks, Grail (GRAL) shares staged a massive recovery this week. The rebound was fueled by a high-profile analyst upgrade and a market correction following what many saw as an overreaction to recent headwinds.
Grail (GRAL) shares outperformed the broader market this week, staging a dramatic recovery following a sharp selloff earlier in the month. Investor sentiment shifted after a key analyst upgrade and a reassessment of the long-term impact of a recent clinical trial setback.
Grail (GRAL) shares staged a significant recovery this week, outperforming the broader market following a period of heavy selling. The rebound was driven by a high-profile analyst upgrade and a shift in investor sentiment regarding the company's multi-cancer early detection (MCED) platform.
Grail (GRAL) stock staged a major recovery this week, outperforming the broader market after a pivotal upgrade from TD Cowen. The rally marks a significant shift in investor sentiment following a volatile period triggered by a CEO transition and clinical trial concerns.
Source: finance.yahoo.com · fool.com
US equity futures signaled a positive open on Friday as investors shifted focus toward the release of fourth-quarter GDP figures. Following a lackluster Thursday session, the market is looking for confirmation of economic resilience while monitoring individual movers like Grail and Candel Therapeutics.
Source: Benzinga · benzinga.com
